{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:26:49Z","timestamp":1790803609861,"version":"4.1.0"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Leptomeningeal metastasis (LM) represents a devastating complication in patients with EGFR-mutant non-small cell lung cancer (NSCLC) who develop resistance to tyrosine kinase inhibitors (TKIs). The management of LM after TKI resistance poses significant clinical challenges due to the heterogeneity of tumor staging, diverse resistance mechanisms, and limited penetration of systemic therapies across the blood\u2013brain barrier (BBB). Current treatment strategies lack standardized protocols and require careful consideration of tumor burden, resistance patterns, and patient-specific factors. This narrative review systematically summarizes recent clinical studies, guidelines, and expert consensus addressing therapeutic decision-making in this setting. This review emphasizes multimodal clinical decision-making, integrating targeted therapies, intrathecal drug administration, radiotherapy, and intracranial pressure relief devices, with discussion of emerging immunological strategies. Although combining these therapies can improve neurological prognosis and survival rates for some patients, toxicity, the unpredictability of efficacy, and the logistical challenges of multidisciplinary treatment remain significant obstacles. To address this issue, we outline a clinical decision-making pathway aimed at helping physicians optimize and personalize treatment regimens. Looking ahead, improving our methods for identifying drug resistance mechanisms, optimizing central nervous system (CNS) drug delivery, and building stronger collaborative care models will be crucial for improving the prognosis of this vulnerable group.<\/jats:p>","DOI":"10.3389\/fneur.2026.1737679","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:40:12Z","timestamp":1779338412000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment decision-making for leptomeningeal metastasis after TKI resistance in EGFR-mutant lung cancer: a comprehensive review on staging, resistance patterns, and multimodal interventions"],"prefix":"10.3389","volume":"17","author":[{"given":"Guo-Qiang","family":"Song","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Changxing County Hospital of Traditional Chinese Medicine","place":["Changxing County, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-li","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Changxing County People's Hospital","place":["Changxing County, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-jie","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Changxing County Hospital of Traditional Chinese Medicine","place":["Changxing County, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-meng","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Changxing County Hospital of Traditional Chinese Medicine","place":["Changxing County, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-qiang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Changxing County Hospital of Traditional Chinese Medicine","place":["Changxing County, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s12032-023-02125-3","article-title":"Exosomal non-coding RNAs-mediated EGFR-TKIs resistance in NSCLC with EGFR mutation","volume":"40","author":"Cheng","year":"2023","journal-title":"Med Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin Cancer Res"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"113942","DOI":"10.1016\/j.biopha.2022.113942","article-title":"AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models","volume":"156","author":"Polonio-Alcal\u00e1","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1158\/1078-0432.CCR-21-3359","article-title":"HER3 augmentation via blockade of EGFR\/AKT signaling enhances anticancer activity of HER3-targeting patritumab deruxtecan in EGFR-mutated non-small cell lung cancer","volume":"28","author":"Yonesaka","year":"2022","journal-title":"Clin Cancer Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1209947","DOI":"10.3389\/fimmu.2023.1209947","article-title":"Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"13264","DOI":"10.18632\/aging.203011","article-title":"Tumor-derived exosomal circRNA_102481 contributes to EGFR-TKIs resistance via the miR-30a-5p\/ROR1 axis in non-small cell lung cancer","volume":"13","author":"Yang","year":"2021","journal-title":"Aging"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"8865","DOI":"10.3390\/curroncol30100640","article-title":"Fluctuation of acquired resistance mutations and re-challenge with EGFR TKI in metastatic NSCLC: a case report","volume":"30","author":"Falk","year":"2023","journal-title":"Curr Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12890-023-02472-x","article-title":"Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis","volume":"23","author":"Hu","year":"2023","journal-title":"BMC Pulm Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.3390\/cells11101694","article-title":"Mediating EGFR-TKI resistance by VEGF\/VEGFR autocrine pathway in non-small cell lung cancer","volume":"11","author":"Osude","year":"2022","journal-title":"Cells"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"102664","DOI":"10.1016\/j.ctrv.2023.102664","article-title":"The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer","volume":"122","author":"Ciardiello","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/1078-0432.CCR-22-1585","article-title":"Leptomeningeal metastasis from non-small cell lung cancer and current landscape of treatments","volume":"29","author":"Ozcan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/1759-7714.13300","article-title":"Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples","volume":"11","author":"Ma","year":"2020","journal-title":"Thoracic Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1038\/s41467-023-40793-x","article-title":"Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis","volume":"14","author":"Skakodub","year":"2023","journal-title":"Nat Commun"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11060-023-04471-8","article-title":"Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases","volume":"165","author":"Bai","year":"2023","journal-title":"J Neuro-Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013Pemetrexed in EGFR T790M\u2013positive lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.annonc.2020.06.017","article-title":"A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy","volume":"31","author":"Park","year":"2020","journal-title":"Ann Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"107475","DOI":"10.1016\/j.lungcan.2024.107475","article-title":"Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis","volume":"188","author":"Wu","year":"2024","journal-title":"Lung Cancer"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"108593","DOI":"10.1016\/j.lungcan.2025.108593","article-title":"Genomic profiling and prognostic factors of leptomeningeal metastasis in EGFR-mutant NSCLC after resistant to third-generation EGFR-tyrosine kinase inhibitors","volume":"205","author":"Xie","year":"2025","journal-title":"Lung Cancer"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"108715","DOI":"10.1016\/j.lungcan.2025.108715","article-title":"Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns","volume":"207","author":"Zhang","year":"2025","journal-title":"Lung Cancer"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR -mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR -mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1056\/NEJMoa2510308","article-title":"Survival with osimertinib plus chemotherapy in EGFR -mutated advanced NSCLC","volume":"394","author":"J\u00e4nne","year":"2026","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.3390\/cancers14163983","article-title":"Ablative radiotherapy as a strategy to overcome TKI resistance in EGFR-mutated NSCLC","volume":"14","author":"Novak","year":"2022","journal-title":"Cancer"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11060-025-05045-6","article-title":"Local cranial radiation combined with third-generation tyrosine kinase inhibitors improve leptomeningeal metastasis disease-free survival in patients with EGFR-mutated non-small cell lung cancer and brain metastasis","volume":"174","author":"Wang","year":"2025","journal-title":"J Neuro-Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3332\/ecancer.2024.1792","article-title":"Intrathecal pemetrexed in NSCLC patients with leptomeningeal metastasis","volume":"18","author":"Noronha","year":"2024","journal-title":"Ecancermedicalscience"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jtho.2024.09.1385","article-title":"High-dose furmonertinib in patients with EGFR-mutated NSCLC and leptomeningeal metastases: a prospective real-world study","volume":"20","author":"Chen","year":"2025","journal-title":"J Thorac Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e70219","DOI":"10.1002\/ccr3.70219","article-title":"Osimertinib as salvage therapy in advanced non-small cell lung cancer after aumolertinib resistance with T790M mutation: a case report","volume":"13","author":"Tang","year":"2025","journal-title":"Clin Case Reports"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.ccell.2024.09.012","article-title":"Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade","volume":"42","author":"Fu","year":"2024","journal-title":"Cancer Cell"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1016\/j.immuni.2024.10.009","article-title":"TKI resistance in brain metastasis: a CTLA4 state of mind","volume":"57","author":"Donders","year":"2024","journal-title":"Immunity"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/1759-7714.13296","article-title":"Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor","volume":"11","author":"Kwon","year":"2020","journal-title":"Thoracic Cancer"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3171\/2022.11.JNS221888","article-title":"Leptomeningeal metastasis in patients with non-small cell lung cancer after stereotactic radiosurgery for brain metastasis","volume":"139","author":"Chiang","year":"2023","journal-title":"J Neurosurg"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"5906","DOI":"10.3390\/curroncol30060442","article-title":"Leptomeningeal metastasis: a review of the pathophysiology, diagnostic methodology, and therapeutic landscape","volume":"30","author":"Nguyen","year":"2023","journal-title":"Curr Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.radonc.2019.11.010","article-title":"Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: a systematic review and meta-analysis of multidisciplinary approaches","volume":"144","author":"Singh","year":"2020","journal-title":"Radiother Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/nop\/npae118","article-title":"Risk factors for type I leptomeningeal metastasis derived from non-small cell lung cancer and the impact of treatment for brain metastases on its development","volume":"12","author":"Iuchi","year":"2025","journal-title":"Neuro Oncol Pract"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1200\/JCO.2016.66.6487","article-title":"Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid","volume":"34","author":"Pentsova","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cell.2017.02.025","article-title":"Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis","volume":"168","author":"A","year":"2017","journal-title":"Cell"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.21037\/apm-21-321","article-title":"Successful treatment using targeted therapy, radiotherapy, and intrathecal chemotherapy in a patient with leptomeningeal metastasis with an epidermal growth factor receptor exon 20 insertion mutation: a case report","volume":"11","author":"Ma","year":"2022","journal-title":"Ann Palliative Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1186\/s12885-021-08581-2","article-title":"Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Cancer"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e58209","DOI":"10.7759\/cureus.58209","article-title":"Leptomeningeal metastasis: a rare complication of non-small cell lung cancer","volume":"16","author":"Schalet","year":"2024","journal-title":"Cureus"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/RLU.0000000000003575","article-title":"Detection of cauda equine syndrome with 18F-FDG PET\/CT and leptomeningeal metastasis by 68Ga-DOTATATE in the same patient with large cell neuroendocrine carcinoma of lung","volume":"46","author":"Arslan","year":"2021","journal-title":"Clin Nucl Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2176\/jns-nmc.2022-0113","article-title":"Solitary leptomeningeal metastasis from lung cancer: a case report","volume":"9","author":"Yokawa","year":"2022","journal-title":"NMC Case Rep J"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.12998\/wjcc.v10.i5.1723","article-title":"Unusual magnetic resonance imaging findings of brain and leptomeningeal metastasis in lung adenocarcinoma: a case report","volume":"10","author":"Li","year":"2022","journal-title":"World J Clin Cases"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3779\/j.issn.1009-3419.2022.102.25","article-title":"Advances in diagnosis and treatment of leptomeningeal metastasis of lung cancer","volume":"25","author":"Gao","year":"2022","journal-title":"Zhongguo Fei Ai Za Zh"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/dc.25217","article-title":"Cytopathological differential diagnosis of malignant tumor cells in the cerebrospinal fluid: a retrospective analysis","volume":"51","author":"Ruotolo","year":"2023","journal-title":"Diagn Cytopathol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1186\/s12885-022-09597-y","article-title":"Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing","volume":"22","author":"Yang","year":"2022","journal-title":"BMC Cancer"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1111\/1759-7714.14592","article-title":"Genotyping of cerebrospinal fluid in lung cancer patients with leptomeningeal metastasis","volume":"13","author":"Nie","year":"2022","journal-title":"Thorac Cancer"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"7968","DOI":"10.12998\/wjcc.v10.i22.7968","article-title":"Early detection of circulating tumor DNA and successful treatment with osimertinib in thr790met-positive leptomeningeal metastatic lung cancer: a case report","volume":"10","author":"Xu","year":"2022","journal-title":"World J Clin Cases"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"e683","DOI":"10.1016\/j.wneu.2024.04.146","article-title":"An evaluation of risk factors for intracranial metastases of sarcomas: a systematic review and meta-analysis","volume":"187","author":"Nguyen","year":"2024","journal-title":"World Neurosurg"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"664420","DOI":"10.3389\/fonc.2022.664420","article-title":"Cerebrospinal fluid cell-free DNA-based detection of high level of genomic instability is associated with poor prognosis in NSCLC patients with leptomeningeal metastases","volume":"12","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11060-025-04938-w","article-title":"Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single-center retrospective study","volume":"172","author":"Zhuang","year":"2025","journal-title":"J Neuro-Oncol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"107572","DOI":"10.1016\/j.clineuro.2022.107572","article-title":"Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer","volume":"225","author":"Liu","year":"2023","journal-title":"Clin Neurol Neurosurg"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"oyaf291","DOI":"10.1093\/oncolo\/oyaf291","article-title":"Intrathecal pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: a clinical efficacy and multiplex liquid proteomics exploration study","volume":"30","author":"Wang","year":"2025","journal-title":"Oncologist"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cllc.2024.02.001","article-title":"A retrospective real-world study of prognostic factors associated with EGFR mutated lung cancer with leptomeningeal metastasis","volume":"25","author":"Wu","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3892\/ol.2025.14947","article-title":"Clinical outcome analysis of different first- and second-generation EGFR-tyrosine kinase inhibitors in untreated patients with EGFR-mutated non-small cell lung cancer with baseline brain metastasis","volume":"29","author":"Hsu","year":"2025","journal-title":"Oncol Lett"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3171\/2022.8.JNS221175","article-title":"Multidisciplinary management of patients with non-small cell lung cancer with leptomeningeal metastasis in the tyrosine kinase inhibitor era","volume":"138","author":"Chen","year":"2023","journal-title":"J Neurosurg"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","article-title":"EANO\u2013ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun","year":"2017","journal-title":"Ann Oncol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/CMAR.S347323","article-title":"Systematic immunological level determined the prognosis of leptomeningeal metastasis in lung cancer","volume":"14","author":"Hong","year":"2022","journal-title":"Cancer Manag Res"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"550","DOI":"10.21037\/jtd.2019.12.122","article-title":"Detection of plasma T790M mutation after the first generation EGFR-TKI resistance of non-small cell lung cancer in the real world","volume":"12","author":"Li","year":"2020","journal-title":"J Thorac Dis"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1039\/d4md00384e","article-title":"Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019-2024)","volume":"15","author":"Das","year":"2024","journal-title":"RSC Med Chem"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s11864-022-01022-7","article-title":"New strategies and novel combinations in EGFR TKI-resistant non-small cell lung cancer","volume":"23","author":"Girard","year":"2022","journal-title":"Curr Treat Options in Oncol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1158\/0008-5472.CAN-22-0770","article-title":"MET-induced CD73 restrains STING-mediated immunogenicity of EGFR-mutant lung cancer","volume":"82","author":"Yoshida","year":"2022","journal-title":"Cancer Res"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3892\/ol.2022.13528","article-title":"Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma","volume":"24","author":"Sun","year":"2022","journal-title":"Oncol Lett"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"107123","DOI":"10.1016\/j.phrs.2024.107123","article-title":"PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: clinical challenges and opportunities","volume":"202","author":"Liu","year":"2024","journal-title":"Pharmacol Res"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"118135","DOI":"10.1016\/j.ejmech.2025.118135","article-title":"Overcoming EGFR mutation resistance: dual inhibition strategies using TKIs in non-small cell lung cancer therapy","volume":"300","author":"Sivam","year":"2025","journal-title":"Eur J Med Chem"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"12886","DOI":"10.21037\/apm-21-2016","article-title":"Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy","volume":"10","author":"Lu","year":"2021","journal-title":"Ann Palliative Med"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.12998\/wjcc.v12.i20.4405","article-title":"Advanced lung adenocarcinoma with EGFR 19-del mutation transformed into SCC after EGFR-tyrosine kinase inhibitors treatment: a case report","volume":"12","author":"Ji","year":"2024","journal-title":"World J Clin Cases"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3892\/mco.2025.2857","article-title":"Molecular mechanisms and therapeutic strategies for small-cell lung cancer transformation after TKI therapy in EGFR-mutated lung adenocarcinoma (review)","volume":"23","author":"Zhang","year":"2025","journal-title":"Mol Clinic Oncol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.21037\/tlcr-21-572","article-title":"Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review","volume":"10","author":"Liu","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.21037\/jtd-23-818","article-title":"Epithelial-mesenchymal transition is associated with osteopontin-induced EGFR-TKI resistance in EGFR mutant non-small cell lung cancer","volume":"15","author":"Chen","year":"2023","journal-title":"J Thorac Dis"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1177\/17588359241289648","article-title":"Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first\u2212\/second-generation EGFR-TKIs","volume":"16","author":"Ma","year":"2024","journal-title":"Therapeut Adv Med Oncol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/14737140.2023.2170879","article-title":"Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance","volume":"23","author":"Ding","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s11060-024-04616-3","article-title":"Prognostic impact of clinical and radiological factors on leptomeningeal metastasis from solid cancers","volume":"167","author":"Nakagawa","year":"2024","journal-title":"J Neuro-Oncol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/1759-7714.13738","article-title":"Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: a phase II single-arm prospective clinical trial","volume":"12","author":"Lu","year":"2021","journal-title":"Thoracic Cancer"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"877279","DOI":"10.3389\/fonc.2022.877279","article-title":"Olaparib combined with dacomitinib in osimertinib-resistant brain and leptomeningeal metastases from non-small cell lung cancer: a case report and systematic review","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2174\/0115680096276133231201061114","article-title":"Treatment advances in lung cancer with leptomeningeal metastasis","volume":"24","author":"Meng","year":"2024","journal-title":"Curr Cancer Drug Targets"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1001\/jamaoncol.2025.3007","article-title":"Proton craniospinal irradiation for patients with leptomeningeal metastasis: a randomized clinical trial","volume":"11","author":"Yang","year":"2025","journal-title":"JAMA Oncol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.3390\/cancers13194926","article-title":"Molecular mechanism of EGFR-TKI resistance in EGFR-mutated non-small cell lung cancer: application to biological diagnostic and monitoring","volume":"13","author":"Reita","year":"2021","journal-title":"Cancer"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"105807","DOI":"10.1016\/j.esmoop.2025.105807","article-title":"COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib","volume":"10","author":"Peled","year":"2025","journal-title":"ESMO Open"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3760\/cma.j.cn112137-20211009-02231","article-title":"Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis","volume":"102","author":"Xu","year":"2022","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1257592","DOI":"10.3389\/fphar.2023.1257592","article-title":"Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V\/H835L using aumolertinib: a case report and literature review","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"202","DOI":"10.7759\/cureus.92202","article-title":"Anaplastic lymphoma kinase (ALK) fusion as a resistance mechanism to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors with complete response after osimertinib and alectinib: a case report and literature review","volume":"17","author":"Cheung","year":"2025","journal-title":"Cureus"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.21037\/apm-20-2086","article-title":"Multiple combination therapy based on intrathecal pemetrexed in non-small cell lung cancer patients with refractory leptomeningeal metastasis","volume":"9","author":"Miao","year":"2020","journal-title":"Ann Palliat Med"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"e40703","DOI":"10.1016\/j.heliyon.2024.e40703","article-title":"Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastases","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/CAD.0000000000001748","article-title":"Overcoming refractory leptomeningeal metastasis in nonsmall cell lung cancer with intrathecal pemetrexed and osimertinib: a case report","volume":"36","author":"Xue","year":"2025","journal-title":"Anti-Cancer Drugs"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"e795","DOI":"10.1097\/CAD.0000000000001222","article-title":"Complete remission in leptomeningeal metastasis of NSCLC with rare EGFR-SEPT14 fusion treated with osimertinib combined with intrathecal chemotherapy with pemetrexed","volume":"33","author":"Zheng","year":"2022","journal-title":"Anti-Cancer Drugs"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"108641","DOI":"10.1016\/j.lungcan.2025.108641","article-title":"Advances in the treatment of brain metastases in EGFR-mutant non-small cell lung cancer","volume":"206","author":"Wang","year":"2025","journal-title":"Lung Cancer"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.21037\/jtd-23-841","article-title":"Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent EGFR exon 19 deletion and TP53 comutation: a case report","volume":"15","author":"Qin","year":"2023","journal-title":"J Thorac Dis"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13014-020-01627-y","article-title":"Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study","volume":"15","author":"Zhen","year":"2020","journal-title":"Radiat Oncol"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00066-021-01814-0","article-title":"Successful salvage of recurrent leptomeningeal disease in large cell neuroendocrine lung cancer with stereotactic radiotherapy","volume":"197","author":"Lee","year":"2021","journal-title":"Strahlentherapie Und Onkologie"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.21037\/jtd-2024-2047","article-title":"Efficacy evaluation of tyrosine kinase inhibitors for advanced non-small cell lung cancer patients with leptomeningeal metastasis","volume":"17","author":"Wang","year":"2025","journal-title":"J Thorac Dis"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"e0210074","DOI":"10.1371\/journal.pone.0210074","article-title":"Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: a single-center retrospective study","volume":"14","author":"Mitsuya","year":"2019","journal-title":"PLoS One"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"e20690","DOI":"10.1016\/j.heliyon.2023.e20690","article-title":"Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R\/T790M or L858R\/S768I mutations: two case reports","volume":"9","author":"Li","year":"2023","journal-title":"Heliyon"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"e70088","DOI":"10.1111\/1759-7714.70088","article-title":"Chinese expert consensus on leptomeningeal metastases of lung cancer","volume":"16","author":"Lin","year":"2025","journal-title":"Thoracic Cancer"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"1233198","DOI":"10.3389\/fonc.2023.1233198","article-title":"Successful therapy using high-dose furmonertinib for non-small cell lung cancer with leptomeningeal metastasis: a case report and literature review","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/ajhp\/zxaa197","article-title":"Optimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: clinical benefits and cost-effectiveness","volume":"77","author":"Hirsh","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s40801-023-00383-1","article-title":"Treatment patterns and adverse event-related hospitalization among patients with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer after treatment with EGFR tyrosine kinase inhibitor and platinum-based chemotherapy regimens","volume":"10","author":"Marrett","year":"2023","journal-title":"Drugs Real World Outcomes"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s12032-025-02755-9","article-title":"Targeting exon mutations in NSCLC: clinical insights into LAG-3, TIM-3 pathways, and advances in fourth-generation EGFR-TKIs","volume":"42","author":"Kannan","year":"2025","journal-title":"Med Oncol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"3S75","DOI":"10.1016\/S0007-4551(25)00160-2","article-title":"Standard of care of EGFR mutated metastatic NSCLC in first treatment and beyond progression","volume":"112","author":"Lef\u00e8vre","year":"2025","journal-title":"Bull Cancer"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3892\/ol.2025.15121","article-title":"EGFR mutations in non-small cell lung cancer: classification, characteristics and resistance to third-generation EGFR-tyrosine kinase inhibitors (review)","volume":"30","author":"Tian","year":"2025","journal-title":"Oncol Lett"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"9243","DOI":"10.1007\/s00432-023-04839-3","article-title":"Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting","volume":"149","author":"Kraskowski","year":"2023","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1737679\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:40:31Z","timestamp":1779338431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1737679\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":103,"alternative-id":["10.3389\/fneur.2026.1737679"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1737679","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1737679"}}